Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 2/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577871 | 0.86 | DRD2 (0.48) | DRD2DRD4DRD3LMNAGAA | |
| SCHEMBL5577584 | 0.86 | SCN10A (0.47) | GNRHRSCN2ASCN10ACXCR3TP53 | |
| SCHEMBL5577570 | 0.85 | SMN1; SMN2 (0.53) | LMNAMAPTPOLB | |
| SCHEMBL5577489 | 0.84 | MT-CO2 (0.48) | GNRHRDRD2DRD3LMNAHTR1A | |
| SCHEMBL5577851 | 0.83 | CHRM3 (0.46) | CXCR3LMNAMAPTTP53POLB | |
| SCHEMBL5577730 | 0.82 | CCR1 (0.48) | GNRHRDRD2DRD4DRD3CXCR3 | |
| SCHEMBL5577895 | 0.80 | DRD2 (0.53) | SCN2ASCN10ADRD2DRD4DRD3 | |
| SCHEMBL5577898 | 0.80 | CXCR3 (0.48) | DRD2DRD4CXCR3MAPTTP53 | |
| SCHEMBL5577304 | 0.80 | CXCR3 (0.46) | CXCR3 | |
| SCHEMBL5577938 | 0.79 | CXCR3 (0.44) | CXCR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | GNRHR 3302/4885SCN2A 3455/4885SCN10A 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.